View Item 

Show simple item record

Darbepoetin alfa: An Effective Treatment with Flexible and Simplified Dosing for Anemia in Patients with Cancer
dc.contributor.authorStevenson, James G.en_US
dc.contributor.authorNatale, James J.en_US
dc.date.accessioned2012-03-16T16:00:48Z
dc.date.available2012-03-16T16:00:48Z
dc.date.issued2007-03en_US
dc.identifier.citationStevenson, James G.; Natale, James J. (2007). "Darbepoetin alfa: An Effective Treatment with Flexible and Simplified Dosing for Anemia in Patients with Cancer." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27(3). <http://hdl.handle.net/2027.42/90361>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90361
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherMyelodysplastic Syndromeen_US
dc.subject.otherAnemiaen_US
dc.subject.otherDarbepoetin Alfaen_US
dc.subject.otherMDSen_US
dc.subject.otherCanceren_US
dc.subject.otherChemotherapyen_US
dc.titleDarbepoetin alfa: An Effective Treatment with Flexible and Simplified Dosing for Anemia in Patients with Canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Hospitals and Health Centers, and the College of Pharmacy, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Pharmacy Services, University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, Pennsylvania.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90361/1/phco.27.3.434.pdf
dc.identifier.doi10.1592/phco.27.3.434en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceLyman GH, Glaspy J. Are there clinical benefits with early erythropoietic intervention for chemotherapy‐induced anemia? A systematic review. Cancer 2006; 106: 223 – 33.en_US
dc.identifier.citedreferenceCanon J‐L, Vansteenkiste J, Bodoky G, et al. Randomized, double‐blind, active‐controlled trial of every‐3‐week darbepoetin alfa for the treatment of chemotherapy‐induced anemia. J Natl Cancer Inst 2006; 98: 273 – 84.en_US
dc.identifier.citedreferenceTaylor K, Ganly P, Charu V, et al. Randomized, double‐blind, placebo‐controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy‐induced anemia [abstract]. Blood 2005; 106: abstract 3556.en_US
dc.identifier.citedreferenceSilberstein P, Boccia R, Liu D, et al. Synchronicity: evaluating darbepoetin alfa administered at 300 μg every three weeks to treat chemotherapy‐induced anemia in breast cancer patients. Presented at the 28th annual San Antonio breast cancer symposium, San Antonio, TX, December 811, 2005.en_US
dc.identifier.citedreferenceCanon J‐L, Vansteenkiste J, Bodoky G, et al. Effect of dose reductions on response to 500‐μg darbepoetin alfa administered once every 3 weeks for the treatment of chemotherapy‐induced anemia: analysis from a randomized, double‐blind, active‐controlled trial [abstract]. Blood 2005; 106: abstract 3558.en_US
dc.identifier.citedreferenceSmith RE, Tchekmedyian NS, Chan D, et al. A dose‐finding and schedule‐finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer. Br J Cancer 2003; 88: 1851 – 88.en_US
dc.identifier.citedreferenceAbels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (r‐HuEPO) for the treatment of the anemia of cancer. In: Murphy MJJ, ed. Blood cell growth factors: their present and future use in hematology and oncology; proceedings of the Beijing symposium. Dayton, OH: AlphaMed Press, 1991: 121 – 41.en_US
dc.identifier.citedreferenceQuirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer‐related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19: 4126 – 34.en_US
dc.identifier.citedreferenceCharu V, Belani CP, Gill AN, et al. A controlled, randomized, open‐label study to evaluate the effect of every‐2‐week darbepoetin alfa for anemia of cancer [abstract]. Proc Am Soc Clin Oncol 2004; 23: 741.en_US
dc.identifier.citedreferenceCheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671 – 4.en_US
dc.identifier.citedreferenceGotlib J, Quesada S, Bhamidipati J, et al. Phase II trial of darbepoetin alfa in myelodysplastic syndrome (MDS): preliminary efficacy, safety, and in vitro results [abstract]. Blood 2004; 104: abstract 4737.en_US
dc.identifier.citedreferenceOliva EN, Ronco F, Danova M, et al. Darbepoetin efficacy in myelodysplastic syndrome [abstract]. Blood 2004; 104: abstract 4704.en_US
dc.identifier.citedreferenceMannone L, Gardin C, Quarre MC, et al. High response rate to darbepoetin alfa in “low risk” MDS: results of a phase II study [abstract]. Blood 2004; 104: abstract 69.en_US
dc.identifier.citedreferenceMusto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes. Br J Haematol 2005; 128: 204 – 9.en_US
dc.identifier.citedreferencePatton J, Mun Y, Wallace J. Darbepoetin alfa maintains hemoglobin levels in patients with myelodysplastic syndromes (MDS) after therapeutic interchange from epoetin alfa: results of a retrospective chart review [abstract]. Blood 2004; 104: abstract 4708.en_US
dc.identifier.citedreferenceGabrilove J, Paquette R, Lyons R, et al. A phase 2, single‐arm, open‐label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low‐risk myelodysplastic syndrome [abstract]. Blood 2005; 106: abstract 2541.en_US
dc.identifier.citedreferenceGreenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079 – 88.en_US
dc.identifier.citedreferenceBennett JM, Catovsky D, Daniel MT, et al, for the French‐American‐British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189 – 99.en_US
dc.identifier.citedreferenceHedenus M, Canon J‐L, Kotasek D, et al. Effects of dose adjustment rules on safety during erythropoietic therapy: a retrospective analysis of darbepoetin alfa administered either every 3 weeks or weekly [abstract]. Blood 2005; 106: abstract 3376.en_US
dc.identifier.citedreferenceLeyland‐Jones B, Semiglasov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first‐line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960 – 72.en_US
dc.identifier.citedreferenceHenke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double‐blind, placebo‐controlled trial. Lancet 2003; 362: 1255 – 60.en_US
dc.identifier.citedreferenceCenter for Drug Evaluation and Research, Department of Health and Human Services, Food and Drug Administration. Oncologic drugs advisory committee, May 4, 2004 meeting transcript. Available from http:www.fda.govohrmsdocketsaccder04.htmlOncologic. Accessed September 30, 2005.en_US
dc.identifier.citedreferenceFreemantle N, Yao B, Calvert M, Lillie T. Impact of darbepoetin alfa on transfusion, hemoglobin response, and survival in cancer patients with chemotherapy‐induced anemia: results of a meta‐analysis of randomized, placebo‐controlled trials [abstract]. Blood 2005; 106: abstract 3116.en_US
dc.identifier.citedreferenceLawless G, Wilson‐Royalty M, Meyers J. Epoetin alfa practice pattern usage in community practice sites [abstract]. Blood 2000; 96: 390b.en_US
dc.identifier.citedreferenceLudwig H, Birgegard G, Barrett‐Lee PJ, Krzakowski M. Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European cancer anaemia survey (ECAS) [abstract]. Blood 2002; 100: 234a.en_US
dc.identifier.citedreferenceCella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25: 43 – 6.en_US
dc.identifier.citedreferenceLudwig H, Pecorelli S. Suboptimal hemoglobin levels: do they impact patients and their therapy? Audience responses. Semin Oncol 2000; 27: 18 – 19.en_US
dc.identifier.citedreferenceHolzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002; 13: 965 – 73.en_US
dc.identifier.citedreferenceCella D. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology 2002; 16: 125 – 32.en_US
dc.identifier.citedreferenceCurt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000; 37: 14 – 17.en_US
dc.identifier.citedreferenceBerndt E, Kallich J, Xu X, Erder Haim M., Lee H, Glaspy J. Reductions in anemia and fatigue are associated with improvements in productivity [abstract]. Blood 2002; 100: 876a.en_US
dc.identifier.citedreferenceEgrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half‐life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290 – 9.en_US
dc.identifier.citedreferenceOrtho Biotech Products L.P. Procrit (epoetin alfa) prescribing information. Bridgewater, NJ; 2005.en_US
dc.identifier.citedreferenceElliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotech 2003; 21: 414 – 21.en_US
dc.identifier.citedreferenceAmgen Inc. Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA; 2005.en_US
dc.identifier.citedreferenceAmgen Inc. Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA; 2006.en_US
dc.identifier.citedreferenceMoore K, Fortner B, Okon T. The impact of medical visits on patients with cancer and their caregivers [abstract]. In: Proceedings of the 28th annual congress of the Oncology Nursing Society, Denver, CO, May 1–4, 2003. Washington, DC: Oncology Nursing Society, 2003: abstract 73.en_US
dc.identifier.citedreferenceTauer K, Zhu L, Fortner B. The impact of anemia treatment visits on the patient and their caregiver [abstract]. Proc Am Soc Clin Oncol 2004; 23: 753.en_US
dc.identifier.citedreferenceMeehan KR, Tchekmedyian NS, Smith RE, Kleinman L, Fitzmaurice T, Kallich JD. An activity‐based costing estimate of anemia correction activities in an oncology practice [abstract]. Blood 2002; 100: 502b.en_US
dc.identifier.citedreferenceBeveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long‐acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 2003; 23 ( 12 pt 2): 101S – 9.en_US
dc.identifier.citedreferenceTchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology 2002; 16: 17 – 24.en_US
dc.identifier.citedreferenceJohnston E, Crawford J. The hematologic support of the cancer patient. In: Berger A, Portenoy RK, Weissman DE, eds. Principles and practices of supportive oncology. Philadelphia, PA: Lippincott‐Raven, 1998: 549 – 69.en_US
dc.identifier.citedreferenceMercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303 – 11.en_US
dc.identifier.citedreferenceErslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol 2000; 64: 353 – 8.en_US
dc.identifier.citedreferenceNowrousian MR, Kasper C, Oberhoff C, et al. Pathophysiology of cancer‐related anemia. In: Smyth JF, Boogaerts MA, Ehmer B, eds. rhErythropoietin in cancer supportive treatment. New York: Marcel Dekker, 1996: 13 – 34.en_US
dc.identifier.citedreferenceJelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18: 555 – 9.en_US
dc.identifier.citedreferenceKomrokji R, Bennett JM. The myelodysplastic syndromes: classification and prognosis. Curr Hematol Rep 2003; 2: 179 – 85.en_US
dc.identifier.citedreferenceAlbitar M, Zhou W, Giles F. Myelodysplastic syndrome: from morphology to biology. Curr Hematol Rep 2004; 3: 159 – 64.en_US
dc.identifier.citedreferenceRizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence‐based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303 – 20.en_US
dc.identifier.citedreferenceBokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 2201 – 16.en_US
dc.identifier.citedreferenceNational Comprehensive Cancer Network Inc. NCCN practice guidelines in oncology. Cancer and treatment‐related anemia, version 1, January 23, 2006. Available from http:www.nccn.org. Accessed February 28, 2006.en_US
dc.identifier.citedreferenceGlaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87: 268 – 76.en_US
dc.identifier.citedreferenceVansteenkiste J, Pirker R, Massuti B, et al. Double‐blind, placebo‐controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211 – 20.en_US
dc.identifier.citedreferenceVadhan‐Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy‐induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003; 1: 131 – 8.en_US
dc.identifier.citedreferenceVadhan‐Raj S, Mirtsching B, Gregory SA, et al. Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy‐induced anemia (CIA) [abstract]. Proc Am Soc Clin Oncol 2004; 23: 740.en_US
dc.identifier.citedreferenceGlaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan‐Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit study group. J Clin Oncol 1997; 15: 1218 – 34.en_US
dc.identifier.citedreferenceDemetri GD, Kris M, Wade J, Degos L, Cella D. Quality‐of‐life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit study group. J Clin Oncol 1998; 16: 3412 – 25.en_US
dc.identifier.citedreferenceGabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once‐weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three‐times‐weekly dosing. J Clin Oncol 2001; 19: 2875 – 82.en_US
dc.identifier.citedreferenceThames WA, Smith SL, Schiefele AC, Yao B, Giffin SA, Alley JL. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 μg every 2 weeks in both naïve patients and patients switched from epoetin alfa. Pharmacotherapy 2004; 24: 313 – 23.en_US
dc.identifier.citedreferenceSchwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study to compare the utilization patterns and clinical outcomes of erythropoietic proteins for chemotherapy‐induced anemia. Clin Ther 2003; 25: 2781 – 96.en_US
dc.identifier.citedreferenceHerrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy‐induced anemia. Am J Health Syst Pharm 2005; 62: 54 – 62.en_US
dc.identifier.citedreferencePatton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy‐induced anemia treated in clinical practice. Oncologist 2004; 9: 451 – 8.en_US
dc.identifier.citedreferenceSchwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every‐2‐week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy‐induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9: 696 – 707.en_US
dc.identifier.citedreferenceWaltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005; 10: 642 – 50.en_US
dc.identifier.citedreferenceGlaspy J, Vadhan‐Raj S, Patel R, et al. Randomized comparison of every‐2‐week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy‐induced anemia: the 20030125 study group trial. J Clin Oncol 2006; 24: 2290 – 7.en_US
dc.identifier.citedreferenceSeidenfeld J, Piper M, Bohlius J, et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment Comparative effectiveness review no. 3 (prepared by Blue Cross and Blue Shield Association technology evaluation center evidence‐based practice center under contract no. 290–02–0026). Rockville, MD: Agency for Healthcare Research and Quality, May 2006. Available from http:www.effectivehealthcare.ahrq.govreportsfinal.cfm. Accessed May 31, 2006.en_US
dc.identifier.citedreferenceKotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: results of a double‐blind, placebo‐controlled, randomised study. Eur J Cancer 2003; 39: 2026 – 34.en_US
dc.identifier.citedreferenceGlaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005; 41: 1140 – 9.en_US
dc.identifier.citedreferenceRearden T, Charu V, Saidman B, et al. Results of a randomized study of every three‐week dosing (Q3W) of darbepoetin alfa for chemotherapy‐induced anemia (CIA) [abstract]. Proc Am Soc Clin Oncol 2004; 23: 741.en_US
dc.identifier.citedreferenceBoccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every 3 weeks is effective for the treatment of chemotherapy‐induced anemia. Oncologist 2006; 11: 409 – 17.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.27.3.434.pdf
Size:
111.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.